Industry
Biotechnology
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Loading...
Open
3.42
Mkt cap
10M
Volume
31K
High
3.43
P/E Ratio
3.16
52-wk high
8.98
Low
3.30
Div yield
N/A
52-wk low
3.00
Portfolio Pulse from
November 08, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 4:28 pm
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 5:37 pm
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 11:50 pm
Portfolio Pulse from Benzinga Insights
June 06, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 20, 2024 | 11:19 am
Portfolio Pulse from Benzinga Insights
April 24, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
April 24, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
April 23, 2024 | 8:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.